ClinicalTrials.gg
RecruitingNCT06567977Trimaximize PLUpdated Aug 23, 2024

TriMaximize: A Multicentre, Prospective, Non-interventional Trial in Asthma Patients

An observational study in Asthma, sponsored by Chiesi Poland Sp. z o.o.. Recruiting at 1 site in Poland. Per ClinicalTrials.gov, last updated 2024-08-23.

Sponsored by Chiesi Poland Sp. z o.o. (part of Chiesi Farmaceutici S.p.A.) · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 8 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies in Asthma by Chiesi Farmaceutici S.p.A. — 11 open to participants now, 11 under way, 2 of them phase 3. Asthma · Chiesi Farmaceutici S.p.A..

Planned enrollment
14th of 15
60 · median 300
Started
2024
with 3 others
Observational
15 of 81
6 open now
Primary completion
2025-03
later than 1 of 10 live
Registered
70th of 81
by date

Among the 81 studies in Asthma by Chiesi Farmaceutici S.p.A., this one is the 14th largest by planned enrollment of the 15 observational ones that give a count, is one of 4 that started in 2024, is one of 15 observational ones, reaches primary completion later than 1 of the 10 other live ones, and was the 70th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

11 of the 81 studies in Asthma by Chiesi Farmaceutici S.p.A. are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Asthma by Chiesi Farmaceutici S.p.A., or all of them as a file.
02

Study summary

TriMaximize: A multicentre, prospective, non-interventional trial monitoring therapy pathways of asthma patients treated with an extra-fine ICS/LABA/LAMA single-inhaler triple therapy in a real-world setting and characterizing the effects on health-related outcomes.

Read the detailed description

The goals of asthma therapy for all degrees of disease severity are minimising asthma symptoms, maximising lung function, and preventing asthma exacer-bations. Despite the existing treatment options and differentiated guidelines, 35 % to 45 % of the GINA 4/5 patients suffer from inadequately controlled symptoms. To investigate the cause of unsatisfactory treatment results, it is essential to monitor therapy pathways of asthma patients in a real-world set-ting. Resulting data can be compared to therapy guidelines and generate hy-potheses for future clinical trials.

Trimbow® is a fixed triple therapy containing a long-acting muscarinic antago-nist (LAMA, glycopyrronium), a long-acting beta-adrenergic agonist (LABA, formoterol) and an inhaled corticosteroid (ICS, beclomethasone). Trimbow® MS (medium strength) contains 100 µg beclomethasone whereas Trimbow® HS (high strength) contains 200 µg beclomethasone. Both formulations are investigated in this study.

Trimbow® has shown major clinical benefits in randomised controlled trials. However, the effects of Trimbow® on changes in patients' symptom burden and quality of life, adherence and clinical outcomes have not been yet as-sessed in a real-world asthma patient population.

The primary objective is to describe patient characteristics and therapy path-ways for patients with a diagnosis of moderate to severe asthma who are treated with Trimbow® in real world practice.

Secondary objectives include:

  • To assess asthma control (ACT)
  • To assess quality of life (Mini-AQLQ)
  • To assess treatment adherence (TAI)
  • To analyse parameters of lung function
  • To analyse parameters of small airways disease (FEF 25-75, RV/TLC)
  • To analyse parameters of asthma-related airway inflammation (FeNO)
  • To analyse parameters of persistent airways limitation (reversibility testing FEV1/FVC)
  • To analyse the incidence and the severity of asthma exacerbations
  • To analyse the use of rescue medication
  • To analyse the use of systemic corticosteroids
  • To assess healthcare resource utilisation
  • To assess treatment satisfaction with Trimbow®
  • To assess tolerability of Trimbow® This is a non-interventional, longitudinal, international, multicentre study with prospective data collection. At baseline, the patient's medical history with spe-cial focus on asthma will be collected. The study baseline visit is at the time point of start of treatment with Trimbow®. Trimbow® treatment may have started up to a maximum of 4 weeks prior to inclusion of the patient into this NIS.

The planned observational period per patient should be at least 52 weeks (ob-servational period [OP] I of the study) and can be extended to up to 3 years (OP II of the study). During the observational period, data may be collected approximately every 3 months during the first year (OP I of the study) and thereafter every 6 months (OP II of the study). The present observational plan does not stipulate any study-related procedures or defined time points; only data that are available within the current clinical routine will be collected as documented in the patients' files.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult asthmatic patients

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients ≥ 18 years of age,
  • Patients with confirmed leading diagnosis of asthma with or without concomitant ,
  • Physician decision to start fixed triple therapy with ICS/LABA/LAMA (Trimbow® MS or HS) according to its current authorised indication. The treatment decision must be made independently from participation in this NIS,
  • Patients willing and able to sign an for use of their pseudonymised clinical data within the present non-interventional study.

Exclusion criteria

Exclusion Criteria:

  • Participation in an interventional clinical trial within 30 days prior to en-rolment into the present non-interventional study or planned enrolment in an interventional clinical trial during the observational period.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No

Interventions

  • OtherTrimbow

    Trimbow® is a fixed triple therapy containing a long-acting muscarinic antago-nist (LAMA, Glycopyrronium), a long-acting beta-adrenergic agonist (LABA, Formoterol) and an inhaled corticosteroid (ICS, beclomethasone). Trimbow® has an extra-fine formulation delivered as a controlled dosage aerosol. Trim-bow® is to be applied in accordance with its current marketing authorisation and the guidance specified in the summary of product characteristics (SmPC) in each country.

    Also known as: Trimbow®

06

What researchers measure

Primary outcomes

  1. The primary objective is to describe patient characteristics and therapy path-ways for patients with a diagnosis of moderate to severe asthma who are treated with Trimbow in real world practice.

    Primary outcome measures include: Descriptive analisys of patients demografic Descriptive analisys of patient demographic

    Time frame: 12 months

Secondary outcomes

  1. Assess asthma control (ACT)

    - Assess asthma control (ACT) - Change from baseline in ACT scores

    Time frame: 12 months

  2. Assess quality of life To measure the functional impairments

    - Assess quality of life - Change from baseline in Mini-AQLQ scores

    Time frame: 12 months

  3. Treatment adherence

    - Assess treatment adherence - Change from baseline in TAI scores

    Time frame: 12 months

  4. Lung function

    - Analyse parameters of lung function using spirometry - Change from baseline in FEV1

    Time frame: 12 months

  5. Small airways parameters

    - Analyse parameters of small airways disease - Change from baseline in small airway function measured by pre-dose AUCAX (Area under the curve of reactance) using available oscillometry system

    Time frame: 12 months

  6. Airway inflammation

    - Analyse parameters of asthma-related airway inflammation - Change from baseline in percentage of patients with a fraction of exhaled nitric oxide (FeNO) below or above 20 ppb

    Time frame: 12 months

  7. Persistent airflow limitation

    - Analyse parameters of persistent airflow limitation - Change from baseline in percentage of patients with persistent airflow limitation (PAL); PAL defined as post-BD FEV1 \<80% predicted and post-BD FEV1/FVC Ratio \< 0.7

    Time frame: 12 months

  8. Asthma exacerbations

    - Analyse the incidence of asthma exacerbations - Number of exacerbations 12 months prior to baseline and during study

    Time frame: 12 months

  9. Rescue medication use

    - Analyse use of rescue medication - Use of any rescue medication 7 days prior to baseline and during study 7 days prior to respective visit

    Time frame: 12 months

  10. Systemic corticosteroids use

    - Analyse use of systemic corticosteroids - Use of any systemic corticosteroids 12 months prior to baseline and during study

    Time frame: 12 months

  11. Adverse events occurence

    - Assess adverse events associated with use of Trimbow - Assessment of the number and type of adverse events

    Time frame: 12 months

  12. Retention rate with Trimbow

    - Assess retention rate with Trimbow - Assess continuation of treatment with Trimbow (retention rate of Trimbow) at month 12

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
  • Indywidualna Specjalistyczna Praktyka Lekarska
    Tarnowskie Gory, 42-609, Poland
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2024; primary completion for Mar 2025, 7 months later.

Of 90 industry-sponsored observational studies under Asthma, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 58. This study's planned 7 months is below that.

Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2024
First posted
Aug 23, 2024
StartEst.
Aug 2024
Primary completionEst.
Mar 1, 2025
CompletionEst.
Aug 1, 2025
Last update
Aug 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06567977
Collaborators
Gesellschaft für Therapieforschung mbH
Responsible party
Sponsor
First posted
Aug 23, 2024
Start date
Aug 2024 (estimated)
Primary completion
Mar 1, 2025 (estimated)
Completion
Aug 1, 2025 (estimated)
Last update
Aug 23, 2024

Study contacts

Tomasz Debowski, Md Phd
Contact
t.debowski@chiesi.com
+48-800 506 122 982
Maciej Wojakiewicz, Phd
Contact
m.wojakiewicz@chiesi.com
+48-800 697 400 054

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion